Pancreatic cancer - gemcitabine (TA25)
Fast, easy summary view of NICE guidance on 'gastrointestinal cancers'
NICE has recommended that:
- People with advanced or metastatic (when the cancer has spread to other parts of the body) pancreatic cancer may be treated with gemcitabine as a first line treatment if they have a Karnofsky performance score of 50 or more.
- Karnofsky is a measure given by a health professional to a person's ability to perform certain ordinary tasks: 100 = normal, no complaints, 70 = unable to carry on normal activity, 50 = requires considerable assistance, 40 = disabled, 30 =hospitalisation recommended.
- Gemcitabine should not be used for people with pancreatic cancer who are suitable for surgery that may cure their cancer, or those who have a Karnofsky performance score of less than 50.
- Gemcitabine should not be used as a second line treatment for people with pancreatic cancer, because there is insufficient evidence to support this practice.
- TA25 Pancreatic cancer - gemcitabine: guidance (web format)
- TA25 Pancreatic cancer - gemcitabine: guidance (html)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: gastrointestinal cancers
This page was last updated: 07 April 2014
- Web format
- Full Guidance (PDF)
- TA25 Arweiniad ar ddefnyddio gemcitabine i drin canser pancreatig: deall canllawiau NICE
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.